Abstract Control of phosphate (P i ) homeostasis is essential for many biologic functions and inappropriate low levels of P i in plasma have been suggested to associate with several pathological states, including renal stone formation and stone recurrence. P i homeostasis is achieved mainly by adjusting the renal reabsorption of P i to the body's requirements. This task is performed to a major extent by the Na/Pi cotransporter NaPi-IIa that is speciWcally expressed in the brush border membrane of renal proximal tubules. While the presence of tight junctions in epithelial cells prevents the diVusion and mixing of the apical and basolateral components, the location of a protein within a particular membrane subdomain (i.e., the presence of NaPi-IIa at the tip of the apical microvilli) often requires its association with scaVolding elements which directly or indirectly connect the protein with the underlying cellular cytoskeleton. NaPi-IIa interacts with the four members of the Na + /H + exchanger regulatory factor family as well as with the GABA A -receptor associated protein . Here we will discuss the most relevant Wndings regarding the role of these proteins on the expression and regulation of the cotransporter, as well as the impact that their absence has in P i homeostasis.
Introduction
The need for a proper control of the circulating levels of phosphate (P i ) is illustrated by several pathologies associated with either hypo or hyperphosphatemic states. Thus, hypophosphatemia compromises bone mineralization and may cause cardiac dysfunction, whereas hyperphosphatemia is linked with secondary hyperparathyroidism and reduced life expectancy (for review see [3, 10] ). Plasma levels of P i are kept in the low millimolar range due to the balance between intestinal absorption, bone deposition/ bone resorption, and renal reabsorption (for review see [4] ). Since P i is freely Wltered in the glomerulus, an eYcient renal reabsorption is required to prevent a massive urinary lost of P i that would otherwise have fatal consequences. In this regard, hypophosphatemia increases intrarenal production of 1,25dihydroxyvitamin D 3 (1, 25 (OH) 2 D 3 ) which in turn leads to higher intestinal absorption of P i and Ca ++ , with a concomitant increase in urinary excretion of Ca ++ . Hypercalciuria is the most prevalent metabolic alteration in renal stone disease and recent studies have suggested that renal reabsorption of P i is reduced in stone formers and associates with hypercalciuria [17] . Moreover, renal handling of P i has been proposed as a predictive factor for renal stone recurrence. Among the diVerent hypercalciuric syndromes, hereditary hypophosphatemic rickets with hypercalciuria has been recently shown to associate with mutations in one of the transporters involved in renal reabsorption of P i (for review see [3, 10, 28] ).
Renal reabsorption of phosphate
Reabsorption of P i from the primary urine takes place preferentially along the proximal tubule with very little contribution of the distal segments. Several Na-dependent P i cotransporters from the SLC34 and SLC20 families of solute carriers are expressed in the brush border membrane (BBM) of proximal tubular cells: namely NaPi-IIa (SLC34A1) [8] , NaPi-IIc (SLC34A3) [25] , and PiT2 (SLC20A2) [30] . NaPi-IIa deWcient mice are hypophosphatemic due to an increased urinary excretion of P i despite a heavy upregulation of NaPi-IIc [2] . These Wndings, together with the lack of phenotype of NaPi-IIc deWcient mice regarding P i balance [26] , indicate that NaPi-IIa is the major cotransporter in the murine kidney. Ablation of both NaPi-IIa [7] and NaPi-IIc [26] results in hypercalcemia and hypercalciuria; as mentioned above, these changes are probably due to a 1,25(OH) 2 D 3 -induced upregulation of intestinal Ca ++ absorption. While disregulation of Ca ++ homeostasis results in the formation of renal stones in NaPi-IIa deWcient mice [7] , the absence of NaPi-IIc does not seem to increase renal mineral deposition [26] . In humans, mutations of NaPi-IIa have been reported in patients with hypophosphatemic syndromes [21] ; however, it is not clear whether these mutations alone can account for the hypophosphatemic state [31] . Instead, mutations in NaPi-IIc have been identiWed by several laboratories in a large number of patients with hereditary hypophosphatemic rickets with hypercalciuria (for review see [3, 10] ). It remains to be shown whether this diVerent relative contribution of both cotransporters to overall P i homeostasis in mouse and human represents a species-speciWc phenomena or responds to yet unknown causes.
Within the murine renal proximal tubule NaPi-IIa is expressed preferentially in the S1 segments and decreases progressively toward the S2 and S3 portions [8] . Under normal dietary conditions it is more abundant in juxtamedular than in superWcial nephrons. Its expression in the proximal BBM is under the control of several hormones [parathyroid hormone (PTH), Wbroblast growth factor 23 (FGF23)] and metabolic factors (1,25(OH) 2 D 3 , dietary P i ) that regulate renal reabsorption of P i (for review see [4] ). With few exceptions, factors that increase renal reabsorption of P i (P i deprivation) do so by upregulating the apical expression of NaPi-IIa, whereas factors that reduce renal reabsorption (PTH, FGF23 or high dietary P i ) lead to downregulation of the cotransporter. Thus, understanding the molecular mechanisms that control the apical expression of NaPi-IIa is a central issue in P i homeostasis.
Interaction of NaPi-IIa with PDZ proteins
NaPi-IIa is an integral protein predicted to span the membrane 8-10 times, with cytoplasmic amino and carboxylterminal tails. In order to identify potential NaPi-IIa interacting partners, several intracellular segments of the cotransporter (amino-and carboxyl-terminal tails as well as the last intracellular loop) were Wrst used as bait in yeast two hybrid screenings.
We found that the carboxyl-terminal tail interacts among other partners with the Na + /H + exchanger regulatory factors 1 and 2 (NHERF1/EBP50 and NHERF2/E3KARP) as well as with PDZK1/CAP70/NaPi-Cap1 and PDZK2 (Fig. 1a ) [11] . These last two proteins were recently renamed as NHERF3 and NHERF4, respectively. NHERF1 and NHERF2 contain two PDZ domains (post-synaptic density protein, PSD95; Drosophila disk large tumor suppressor, DlgA; zonula occludens-1 protein, ZO-1) and a carboxyl-terminal Preventing the association of NaPi-IIa with NHERF1 impairs the apical expression of NaPi-IIa (b modify from [13] ): confocal microscopy of OK cells transfected with a plasmid encoding the myc-fused PDZ1 of NHERF1. Cultures were stained for myc-PDZ1 (red), the endogenous NaPi-IIa (green) and actin (white). The patches represent actin-enriched apical microdomains were NaPi-IIa is predominantly enriched. The transfected myc-PDZ1 has a dominant negative eVect, as indicated by the observation that cells expressing myc-PDZ1 have a reduced expression of NaPi-IIa in the apical microvilli despite a normal actin cytoskeleton Moesin-Ezrin-Radixin-Merlin (MERM) binding domain that indirectly connects with actin. NHERF3 and NHERF4 contain four PDZ domains and their binding to the actin cytoskeleton has been proposed to be mediated via association with NHERF1. Indeed, NHERF1/2 were shown to interact with the fourth PDZ domain of NHERF3 [12] . NaPi-IIa interacts speciWcally with the Wrst PDZ domain of NHERF1/2 and with the third PDZ domain of NHERF3/4. In all four cases, the association is strictly dependent on the presence of the last three residues of NaPi-IIa (TRL) that therefore act as a PDZ-binding motif. In our initial screen we found that NHERF3/4 hits represented about 70% of all interacting clones, whereas NHERF1/2 hits contributed to less than 10% [11] . This observation may just reXect the diVerent relative abundance of transcripts in the kidney cDNA library. However, in vitro analysis indicated that the interaction of NaPi-I (a cotransporter which carboxyl-terminal tail has high homology with NaPi-IIa) with NHERF3 is stronger than its association with NHERF1 [12] . The four NHERF isoforms are coexpressed with NaPi-IIa at the BBM of renal proximal tubules, but their membrane expression is not regulated by factors that modulate the apical abundance of the cotransporter.
Interaction of NaPi-IIa with NHERF1: functional eVect
Early experiments showed that removal of just the carboxylterminal TRL residues of NaPi-IIa results in a protein that accumulates massively in the cytoplasm upon transfection in proximal epithelial cells, unlike the wild type cotransporter that is expressed preferentially at the apical membrane [16] . The Wnding that the three terminal residues act as a PDZbinding motif allowed us to clarify the molecular mechanism underlying these early observations. Thus, we could show that preventing the association of NaPi-IIa with NHERF1, by transfecting OK cells only with the interacting PDZ domain of NHERF1 impairs the apical expression of the cotransporter (Fig. 1b) [13] . Together, these Wndings suggested that the association with NHERF1 via the terminal TRL stabilizes the expression of NaPi-IIa at the BBM. Such mechanism was conWrmed when Shenolikar and colleagues published the generation of the NHERF1 knock out. They reported that the absence of NHERF1 results in a reduced expression of NaPi-IIa in the proximal BBM, leading to an increased urinary excretion of P i and hypophosphatemia [27] .
PTH is a phosphaturic hormone that acts by regulating the apical expression of NaPi-IIa. PTH binds to a G-protein coupled receptor able to activate the adenylyl cyclase (AC)/ PKA as well as the phospholipase C (PLC)/PKC pathways. Both cascades lead to endocytosis and lysosomal degradation of NaPi-IIa (for review, see [4] ). The AC eVect seems to be solely mediated via the classical PKA pathway, without contribution of the exchange protein directly activated by cAMP (EPAC) [15] . Unlike NaPi-IIa, NHERF1 is not endocytosed upon PTH treatment [9] , suggesting that the complex of both proteins must be dissociated prior to internalization of the cotransporter (Fig. 2a) . Indeed the amount of NaPi-IIa that co-immunoprecipitates with NHREF is reduced upon incubation with PTH (Fig. 2b) . In addition, incubation with PTH, or pharmacological activation of PKA or PKC, leads to hyperphosphorylation of NHERF (Fig. 2c) , whereas NaPi-IIa does not seem to be phosphorylated either basally or after PTH treatment (Fig. 2d) [9] . Based on these observations, we proposed that phosphorylation of NHERF1 could inhibit its association with NaPi-IIa, thus rendering a cotransporter with reduced stability at the BBM. This hypothesis was later on conWrmed by EJ (1), dissociation of NaPi-IIa/NHERF1 complexes (2) and endocytosis of NaPi-IIa (3). PTH treatment reduces the amount of NaPi-IIa that coimmunoprecipitates (co-IP) with NHERF1 (b [9] ): OK cells were transfected with V5-tagged NaPi-IIa. Cultures were treated with leupeptin (to prevent lysosomal degradation) followed by incubation in the absence (¡) or presence (+) of 1-34 PTH. Upon cellular lysis, NHERF1 was immunoprecipitated with an NHERF antibody, and the immunoprecipitated material was processed for Western blot with V5 and NHERF1 antibodies. *** P · 0.001. PTH treatment leads to phosphorylation of NHERF1 (c [9] ): slices of mouse kidneys were phosphorylated in the presence of 32 P followed by incubation in the absence (¡) or presence (+) of 1-34 PTH. NHERF1 was then pulled down using GST fused to the C-terminal tail of NaPi-I (GST-CT). Upon elution, samples were analyzed for 32 P incorporation (top panels) or processed for Western blot with NHERF1 antibodies (bottom panel). PTH treatment does not induce phosphorylation of NaPi-IIa (b [9] ): kidney slices were phosphorylated in the presence of 32 P and leupeptin followed by incubation in the absence (¡) or presence (+) of 1-34 PTH. NaPi-IIa was pulled down using GST fused to PDZK1 (GST-K1) and process as indicated above. The top panel shows the 32 P autoradiogram and the bottom panel a Western blot with a NaPi-IIa antibody Weinman's group [34] , who reported that PTH-induced dissociation of NaPi-IIa/NHERF1 complexes involves phosphorylation of a serine residue (S77) within the Wrst PDZ domain of NHERF1.
In addition to its role as a scaVold for membrane proteins, NHERF1 is also known to mediate the assembly of intracellular signaling molecules (for review see [33] ). Thus, NHERF1 interacts with both the PTH receptor and PLC, and it has been proposed that NHERF may control the intracellular pathway activated upon PTH binding [18] . We had previously reported that although activation of apical and basolateral PTH receptors results in internalization of NaPi-IIa they do not share similar intracellular pathways. In particular, apical receptors seem to activate preferentially the PKC dependent pathway whereas basolateral receptors signal preferentially via PKA [29] . Therefore, in collaboration with EJ Weinman's group we investigated whether the eVect of 3-34 PTH, a PTH fragment that activates exclusively PKC, is preserved in the absence of NHERF1. Although 3-34 PTH downregulated NaPi-IIa in wild type mice, it failed to do so in NHERF1 knock outs [6] . This failure associated with the inability of PTH to activate PLC in the mutant mice. Since the expression of NHERF1 in the renal epithelia is restricted to the BBM, our Wndings are consistent with the proposal that in the presence of NHERF the PTH receptors (apical) signal via activation of the PLC/ PKC pathway, whereas in the absence of NHERF these receptors (basolateral) would signal preferentially through activation of PKA [18] . Therefore, NHERF does not only control the basal expression of NaPi-IIa but also the intracellular signals that regulate its abundance.
Interaction of NaPi-IIa with NHERF3: functional eVect As mentioned above, NHERF3/4 represented about 70% of all the hits in our yeast two hybrid screen. In addition to NaPi-IIa, NHERF3 also interacts with several other transporters expressed in the proximal BBM (Na + /H + exchanger NHE3, organic cation transporter OCTN1, chloride/formate exchanger CFEX and urate/anion exchanger URAT1) as well as with regulatory factors (NHERF1 or PKA-anchoring protein D-AKAP2) [12] . Due to the presence of 4 PDZ domains, NHERF3 may form a large network of membrane proteins and regulatory factors. Similar to NHERF1, the expression of NHERF3 remains unaVected upon incubation of kidney samples with PTH, suggesting that PTH also destabilizes its association with NaPi-IIa. Although NHERF3 is phosphorylated under basal conditions, PTH or independent activation of PKA or PKC do not regulate the phosphorylated status of the protein (Déliot and Hernando, unpublished observations). This suggests that NHERF3 is not a target for PTH-activated kinases and that the regulated dissociation of NaPi-IIa from NHERF3 does not depend on the same molecular mechanism that its dissociation from NHERF1.
The membrane expression of NaPi-IIa is not altered in NHERF3 deWcient mice that also have normal expression of NHERF1 [5] . Regulation of NaPi-IIa by PTH or in response to pharmacological activation of PKA and PKC is also normal in these animals. Only upon challenging with diets containing high or low P i levels we could detect subtle diVerences between wild type and NHERF3 deWcient mice, namely downregulation of NaPi-IIa in response to high dietary P i is more pronounced in the absence of NHERF3 [5] .
Taken together, the four members of the NHERF family interact with NaPi-IIa in vitro but they do not have redundant roles in vivo. Instead, NHERF1 is speciWcally required for the stabilization of the cotransporter at the apical membrane and its absence is not compensated by the presence of the other isoforms in the BBM.
Interaction of NaPi-IIa with GABARAP: functional eVect
More recently, in collaboration with OW Moe's group we made a new yeast two hybrid screen using as bait the whole NaPi-IIa protein just with the last terminal TRL truncated. This study identiWed the GABA A -receptor associated protein (GABARAP) as a new interacting partner of NaPi-IIa [22] . The domain of GABARAP involved in the interaction is located between residues 36 and 68, a stretch shown previously to mediate association with several other partners, including GABA A receptors [32] . However, the domain of NaPi-IIa responsible for the interaction remains elusive, as our attempts to identify it by using discrete intracellular domains of NaPi-IIa in GST pull down assays failed.
There are a number of studies showing that GABARAP promotes the membrane expression of GABA A -receptors in cell culture; however, the localization of these receptors is normal in GABARAP deWcient mice [20] . We reported that these animals have a reduced urinary excretion of P i associated with upregulation of NaPi-IIa (Fig. 3) [22] . NHERF1 is also heavily upregulated in the mutant mice. The molecular explanation for this Wnding remains unknown but does not seem to involve association of GABARAP with NHERF1. Despite the defect in renal handling, GABARAP deWcient mice have normal levels of P i in serum. This normophosphatemia is most probably due to a compensatory reduction of the intestinal absorption of P i . This compensation is suggested by the Wnding that NaPi-IIb, the major cotransporter involved in intestinal absorption of P i [14, 24] , is downregulated in GABARAP knock outs (Fig. 3 ) [23] . Interestingly, also NaPi-IIb deWcient mice are normophosphatemic: they seem to compensate the reduced intestinal absorption of P i (due to the absence of NaPi-IIb) with an increased renal reabsorption (through upregulation of NaPiIIa) [24] . Within the intestinal tract, NaPi-IIb is located preferentially in the ileum and its expression in under control of 1,25(OH) 2 D 3 (for review see [4] ). The expression of the 25 hydroxyvitamin D-1 hydroxylase (1 -OHase), the enzyme that produces the active form of 1,25(OH) 2 D 3 , is reduced in the kidneys from GABARAP deWcient mice (Fig. 3) , whereas the levels of the catabolic 24 hydroxylase are similar in both the groups [23] . These data are consistent with a reduced renal synthesis of 1,25(OH) 2 D 3 in the mutant mice which in turn lead to a reduced expression of NaPi-IIb. Interestingly, both GABARAP and NaPi-IIb deWcient mice are normocalcemic; however, while urinary excretion of Ca ++ is normal in the absence of GABARAP [23] , it is increased in NaPi-IIb deWcient animals [24] . There is no information regarding the presence of renal mineral deposits in these animals.
Although GABARAP was Wrst identiWed as a ligand of the -subunit of GABA A receptors, it was later on shown to interact with several proteins involved in intracellular traYcking among them the clathrin heavy chain (for review see [19] ). We have evidences that PTH-induced endocytosis of NaPi-IIa takes place at least partially via clathrin-coated pits [1] , opening the question of whether the absence of GABARAP would blunt the hormonal eVect. However, PTH downregulates the expression of NaPi-IIa to comparable levels in wild type and GABARAP deWcient mice. Similarly, there are no diVerences in the adaptation of the cotransporter to acute dietary P i changes [22] .
In summary, NaPi-IIa interacts with the NHERF family of PDZ proteins as well as with GABARAP. The absence of NHERF1 results in reduced apical expression of NaPi-IIa, phosphaturia, hypophosphatemia and impaired PKC-mediated PTH regulation. In contrast, the absence of GABARAP results in increased apical expression of NaPi-IIa, and reduced urinary excretion of P i . However, circulating levels of P i remain normal probably due to an intestinal compensation. Fig. 3 Expression of Na/Pi-cotransporters in the absence of GABA-RAP. GABARAP deWcient mice (KO) shows an increased expression of NaPi-IIa in renal BBM and a reduced expression of NaPi-IIb in BBM from ileum as compared with wild type mice (WT). The net eVect of both changes probably explains the normophosphatemia in the mutant mice. Graphics show the quantiWcation of cotransporters as their ratio to the amount of actin [22, 23] . The mRNAs levels of the 25 hydroxyvitamin D-1 hydroxylase (1 -OHase) are reduced in kidneys from GABARAP deWcient mice; therefore, a low renal production of 1,25(OH) 2 D 3 could be responsible for the reduced expression of NaPiIIb in these mice. The graphic shows the quantiWcation of 1 -OHase mRNA normalized to the hypoxanthine-guanine phosphoribosyltransferase [23] . *P · 0.05, **P · 0.01
